Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 11, 2008

View Archived Issues

Erythropoietin may have antidepressant activity

Iloperidone effective in double-blind schizophrenia trials

Quetiapine treatment assessed in depression, anxiety and alcoholism

Idenix gives update on development of HCV nucleotide prodrugs IDX-184 and IDX-102

Nektar initiates phase II clinical program for PEG-Irinotecan in colorectal cancer

Phase II trial begins for oral PEG-naloxol in opioid-induced bowel dysfunction

Rigel enrolls patients in phase I R-348 trial in immune disorders

Pipex initiates phase II trial of anti-copper Coprexa for Alzheimer's disease

Toyama initiates phase II study for antiinfluenza agent T-705 in Japan

FDA accepts Icagen's IND application for senicapoc for asthma

FDA approves Can-Fite's IND application for phase I study of CF-102 for liver cancer

Pluristem to initiate phase I clinical trials of PLX-PAD for the treatment of limb ischemia

FDA lifts clinical hold on Vion's phase III trial of Cloretazine for acute AML

FDA grants approval to Compellis and Pennington to begin phase I clinical studies of CP-404

FDA grants approval to Chemokine to initiate phase II trial of CTCE-9908 for liver cancer

Emergent BioSolutions reports positive results from phase II clinical study of typhoid vaccine

Vivus initiates DM-230 extension study for patients in the OB-202 study of Qnexa

CTS-21166 reduces plasma amyloid beta in phase I study

Surface Logix's SLx-2101 reduces blood pressure in phase IIa clinical trial

Pharmion and MethylGene initiate phase II clinical trial of MGCD-0103 with Vidaza

BioAlliance Pharma receives marketing authorization for Loramyc in the U.K. and Denmark

Corthera's phase II clinical trial of relaxin in acute heart failure begins

Novel analgesic agents reported in patent literature

New antiinfective agents disclosed in recent patents

Companies claim novel antidiabetic agents in recent patents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...